Stock Market News
Oxford BioMedica signs collaboration agreement with Bioverativ
Gene and cell therapy group Oxford BioMedica announced on Thursday that it has completed a major new collaboration and licence agreement with Bioverativ, for the development and manufacture of lentiviral vectors to treat haemophilia.
The London-listed firm said the agreement included a licence to use its 'LentiVector Enabled' technology, and access to its industrial-scale manufacturing technology.
Under the terms of the agreement, Oxford BioMedica would receive a $5m upfront payment from Bioverativ.
Oxford BioMedica would also be eligible to receive various milestone payments, potentially worth in excess of $100m, and undisclosed royalties on net sales of Bioverativ's lentiviral vector haemophilia products.
Bioverativ would also fund process development and scale-up activities for its lentiviral vector haemophilia products at Oxford BioMedica.
The company said the agreement also allowed for the parties to put in place a clinical supply agreement for GMP manufacturing of haemophilia products at Oxford BioMedica.
"Today's news demonstrates the value of our LentiVector Enabled platform and our leading capabilities and reputation in the industrial scale-up for lentiviral vectors for clinical and commercial supply," said Oxford Biomedica CEO John Dawson.
"Bioverativ's investment in haemophilia gene therapy underlines the potential of lentiviral vectors for use for in vivo gene therapy."
Dawson said the new deal, potentially worth in excess of $100m, demonstrated Oxford BioMedica's strategy of building multiple partnerships with leaders in their therapeutic categories, and would support the group's continued growth.
"Oxford BioMedica is recognised as a world leader in the field of development and manufacturing of lentiviral vectors and we are delighted to be supporting Bioverativ in the development of gene therapy products to treat haemophilia."
The London-listed firm said the agreement included a licence to use its 'LentiVector Enabled' technology, and access to its industrial-scale manufacturing technology.
Under the terms of the agreement, Oxford BioMedica would receive a $5m upfront payment from Bioverativ.
Oxford BioMedica would also be eligible to receive various milestone payments, potentially worth in excess of $100m, and undisclosed royalties on net sales of Bioverativ's lentiviral vector haemophilia products.
Bioverativ would also fund process development and scale-up activities for its lentiviral vector haemophilia products at Oxford BioMedica.
The company said the agreement also allowed for the parties to put in place a clinical supply agreement for GMP manufacturing of haemophilia products at Oxford BioMedica.
"Today's news demonstrates the value of our LentiVector Enabled platform and our leading capabilities and reputation in the industrial scale-up for lentiviral vectors for clinical and commercial supply," said Oxford Biomedica CEO John Dawson.
"Bioverativ's investment in haemophilia gene therapy underlines the potential of lentiviral vectors for use for in vivo gene therapy."
Dawson said the new deal, potentially worth in excess of $100m, demonstrated Oxford BioMedica's strategy of building multiple partnerships with leaders in their therapeutic categories, and would support the group's continued growth.
"Oxford BioMedica is recognised as a world leader in the field of development and manufacturing of lentiviral vectors and we are delighted to be supporting Bioverativ in the development of gene therapy products to treat haemophilia."
Related share prices |
---|
Oxford Biomedica (OXB) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price